ENVB - Enveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical Compounds | Benzinga
Enveric Biosciences (NASDAQ:ENVB) announced the discovery of multiple compounds sourced using its Psybrary platform and proprietary computational chemistry and artificial intelligence (AI) drug-discovery system (PsyAI).
The compounds span seven distinct molecule classes totaling at least 57 unique product opportunities, all protected by Enveric's expansive intellectual property portfolio.
The compounds also represent potential out-licensing opportunities and non-dilutive revenue streams for the company.
The new molecule classes broaden and deepen Enveric's library of assets targeting difficult-to-address mental health disorders, adding to its lead candidate EB-003, a first-in-class neuroplastogen designed to eliminate hallucinations, and EB-002 (formerly EB-373), a next-generation synthetic prodrug of the active metabolite, psilocin.
The compounds include:
- Novel Serotonin-Norepinephrine-Dopamine Reuptake Inhibitors (SNDRI), also known as triple reuptake inhibitors, SNDRIs are an emerging class of medications designed to treat ...